BR100 Increased By (0.39%)
BR30 Increased By (0.47%)
KSE100 Increased By (0.6%)
KSE30 Increased By (0.7%)
AGHA 6.55 Increased By ▲ 0.23 (3.64%)
BECO 4.40 Increased By ▲ 0.13 (3.04%)
BML 62.43 Decreased By ▼ -0.02 (-0.03%)
BOP 31.38 Increased By ▲ 0.15 (0.48%)
CNERGY 11.79 Increased By ▲ 0.20 (1.73%)
CSIL 5.95 Increased By ▲ 0.23 (4.02%)
FCCL 61.12 Decreased By ▼ -0.42 (-0.68%)
FFL 14.88 Decreased By ▼ -0.14 (-0.93%)
FNEL 1.24 Increased By ▲ 0.01 (0.81%)
KEL 6.29 Increased By ▲ 0.03 (0.48%)
KOSM 6.00 Increased By ▲ 0.44 (7.91%)
LOTCHEM 24.85 Increased By ▲ 0.17 (0.69%)
MLCF 104.13 Increased By ▲ 0.05 (0.05%)
NBP 174.66 Decreased By ▼ -0.62 (-0.35%)
NCPL 52.83 Increased By ▲ 0.06 (0.11%)
NPL 54.48 Increased By ▲ 0.36 (0.67%)
OGDC 315.35 Increased By ▲ 1.96 (0.63%)
PACE 9.41 Increased By ▲ 0.21 (2.28%)
PAEL 35.62 Decreased By ▼ -0.18 (-0.5%)
PIBTL 13.71 Increased By ▲ 0.24 (1.78%)
PPL 223.38 Increased By ▲ 1.57 (0.71%)
PRL 80.79 Increased By ▲ 1.71 (2.16%)
PTC 47.15 Increased By ▲ 0.30 (0.64%)
SSGC 24.15 Increased By ▲ 0.28 (1.17%)
TBL 9.25 Decreased By ▼ -0.06 (-0.64%)
TELE 7.53 Increased By ▲ 0.14 (1.89%)
TPL 24.89 Decreased By ▼ -0.22 (-0.88%)
TPLP 12.88 Increased By ▲ 0.37 (2.96%)
TREET 26.10 Decreased By ▼ -0.15 (-0.57%)
TRG 53.75 Increased By ▲ 0.31 (0.58%)
World

Switzerland increases order for Moderna's COVID-19 vaccine

  • The vaccine, mRNA-1273, is currently under review in the country, and Moderna said it could ship it as soon as regulatory approval is granted.
Published Updated
By

Switzerland has increased its confirmed order for Moderna Inc's COVID-19 vaccine doses to 7.5 million from 4.5 million, the U.S. company said on Tuesday.

The vaccine, mRNA-1273, is currently under review in the country, and Moderna said it could ship it as soon as regulatory approval is granted.

The company has submitted applications seeking emergency use authorization in the United States and the European Union after full results from a late-stage study showed the vaccine was 94.1% effective with no serious safety concerns.

Vaccine doses to be supplied to the country will be sourced from Moderna's European production capacity with its partner Swiss contract drug manufacturer Lonza and Rovi of Spain for fill-finish services.

Moderna, whose vaccine requires two doses per person, has said it remains on track to produce between 500 million and 1 billion doses annually by 2021.

Comments

Comments are closed for this article.